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Abstract 23 
Background: Understanding the factors that drive recurrence and radiosensitivity in brain metastases 24 
would improve prediction of outcomes, treatment planning and development of therapeutics. We 25 
investigated the expression of known Metastasis-Inducing Proteins in human brain metastases. 26 
Methods: Immunohistochemistry on metastases removed at neurosurgery from 138 patients to 27 
determine the degree and pattern of expression of the proteins S100A4, S100P, AGR2, osteopontin 28 
(OPN) and the DNA repair marker FANCD2. Validation of significant findings in a separate 29 
prospective series with investigation of intra-tumoral heterogeneity using image-guided sampling. 30 
Assessment of S100A4 expression in brain metastatic and non-metastatic primary breast carcinomas.  31 
Results: There was widespread staining for OPN, S100A4, S100P and AGR2 in human brain 32 
metastases. Positive staining for S100A4 was independently associated with a shorter time to 33 
intracranial progression after resection in multivariate analysis (hazard ratio for negative over positive 34 
staining = 0.17, 95% CI: 0.04 – 0.74, p=0.018). S100A4 was expressed at the leading edge of brain 35 
metastases in image guided sampling and overexpressed in brain-metastatic versus non-brain 36 
metastatic primary breast carcinomas. Staining for OPN was associated with a significant increase in 37 
survival time after postoperative whole brain radiotherapy in retrospective (OPN negative 3.43 38 
months, 95% CI: 1.36 – 5.51 vs. OPN positive, 11.20 months 95% CI: 7.68 – 14.72, Log Rank test, 39 
p<0.001) and validation populations. 40 
Conclusions: Proteins known to be involved in cellular adhesion and migration in vitro and metastasis 41 
in vivo are significantly expressed in human brain metastases and may be useful biomarkers of 42 
intracranial progression and radiosensitivity.  43 
 44 
 45 
 46 
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Introduction 47 
Brain metastases (BMs) are common brain tumours in adults with a steeply rising incidence due to the 48 
increased use of brain imaging in asymptomatic patients and prolonged survival from solid organ 49 
cancers (Owonikoko et al, 2014). There are no known biological markers that are routinely used to 50 
predict patient outcomes in BMs. Clinical factors are combined to generate predictions of overall 51 
survival, but cannot predict intracranial progression and the various models are not individualised to 52 
each patient, even if different primary cancer types are assessed separately (Sperduto et al, 2010).  53 
We have previously identified two groups of proteins in the rat mammary model system that can 54 
induce metastasis and are associated with clinical outcomes in patients with breast (de Silva Rudland 55 
et al, 2011) and other solid organ cancers. S100A4 and S100P are small calcium-dependent regulatory 56 
molecules that are suggested to work by inducing cellular migration and invasion directly (Gross et al, 57 
2014).  S100A4 is active in the brain microenvironment (Dmytriyeva et al, 2012), elevated levels are 58 
associated with a metastatic phenotype, it cooperates with growth-inducing activated oncogenes to 59 
yield growing metastases and carcinomas in S100A4 knockout mice do not metastasise to brain 60 
(Bresnick et al, 2015). The second group – osteopontin (OPN) and anterior gradient 2 (AGR2) - work 61 
primarily by inducing cellular adhesion to the extracellular matrix (ECM) that then allows migration 62 
to take place (Liu et al, 2005; Moye et al, 2004). OPN binds the cell surface integrins αVβ3 / αVβ5 with 63 
the latter widely expressed in human BMs and their microenvironment (Berghoff et al, 2014; 64 
Schittenhelm et al, 2013). The integrin αVβ3 / αVβ5 inhibitor cilengitide induces cellular detachment 65 
and apoptosis, and reduces proliferation in a panel of brain metastatic breast cancer cell lines 66 
(Lautenschlaeger et al, 2013). AGR2 has been shown to be necessary and sufficient for migration in 67 
vitro in a glioblastoma cell line (Hong et al, 2013). Finally, the underlying change that is believed to 68 
result in selection for overexpression of these Metastasis-Inducing Proteins (MIPs) is a failure of 69 
double-stranded DNA repair in a progenitor cell and in the breast this process is identified by 70 
immunohistochemical loss of the Fanconi anaemia protein, complementation group D2 (FANCD2) 71 
(Rudland et al, 2010). Notably other closely related proteins in this family (Fanconi anaemia protein, 72 
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complementation group A & G) have recently been shown to be overexpressed in BMs compared to 73 
the primary breast carcinoma in paired human samples (Woditschka et al, 2014).  74 
We therefore studied these MIPs in human brain metastases to investigate if they are overexpressed 75 
and if their expression may be useful markers of clinical outcomes such as survival and progression. 76 
 77 
Materials and methods 78 
Patients and specimens 79 
Patients with a diagnosis of brain metastasis were identified from histopathology records between 80 
2005 and 2012 at a single institution and formalin-fixed, paraffin-embedded specimens were obtained 81 
in 138 cases. Full clinical information was gathered and is summarised in Table 1. For validation and 82 
investigation of intra-tumoral heterogeneity, 24 consecutive patients were included who underwent 83 
neurosurgical resection of a solitary supratentorial metastasis in non-eloquent brain by image-guided 84 
craniotomy as part of their standard care from 2014 - 2015. Clinical details are listed in 85 
Supplementary Data (Table S1) and surgical, MRI techniques have been described previously 86 
(Zakaria & Jenkinson, 2014). Ethical approval was granted for this study within the Walton Research 87 
Tissue Bank for which all patients undergoing surgery are asked to give written informed consent 88 
(NRES 11/WNo03/2). Further ethical approval for use of archival and primary breast carcinoma 89 
specimens was granted by the UK Health Research Authority (NRES 12/NW/0778).  90 
 91 
Immunohistochemistry  92 
Histological sections were cut at 4 µm on APES coated slides, dewaxed in xylene and rehydrated 93 
through graded ethanol to water. Firstly, endogenous peroxidase activity in the tissue sections was 94 
blocked by immersing the slides in 100% methanol containing 0.05% (v/v) H202 for 20 min at room 95 
temperature. Sections were then incubated in a moisture chamber with antibodies diluted in 96 
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phosphate-buffered saline (PBS) containing 1% (w/v) bovine serum albumen (BSA) pH 7.4 as 97 
described for each stain further in Supplementary Data.   98 
 99 
Assessment of staining 100 
Slides were analysed independently by two observers using light microscopy (RZ, NR) and 101 
corroborated by a senior neuropathologist (DC). The percentage of nuclear and/or cytoplasm stained 102 
tumour cells was recorded from well-separated sections of each specimen, 10 fields per section at 103 
×200 magnification, at a minimum of 200 cells per field in a rigorous fashion as described previously 104 
(Wang et al, 2006). There was agreement on positive staining (1% or above of cells positively stained 105 
to any degree (de Silva Rudland et al, 2011)) in 94% of slides scored, with a kappa statistic of 0.884. 106 
Slides were photographed using a Leica DFC310FX camera attached to a DM2000 microscope with 107 
the LAS V3 software suite (Leica microsystems, 2014) with no additional filtering or post processing 108 
of images.  109 
 110 
Statistical methods 111 
Time from surgery to death was recorded as overall survival (OS) and non-cancer deaths or those lost 112 
to follow up censored at last recorded follow up. Progression free survival (PFS) was recorded as time 113 
from surgery to documented intracranial progression as assessed by neuroradiologists using standard 114 
(RANO) criteria (Quant & Wen, 2011). Patients who died before this point were censored at the last 115 
date of follow up where there was no evidence of progression. Proportions were assessed using 116 
Fisher’s two-sided exact test. Time-to-event comparisons were made using Kaplan-Meier survival 117 
analysis with Log Rank tests and multivariate analyses conducted using Cox’s method. Data 118 
processing was performed using SPSS version 22.0 (IBM, Chicago, IL) and R version 3.10 (R Core 119 
Team, 2013). 120 
 121 
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Results 122 
Exploratory immunohistochemical staining  123 
Of 138 BMs assessed retrospectively, sixteen were negatively stained for OPN (11.6%) and 122 124 
(88.4%) were positively stained in varying proportions and intensities. This staining was mainly 125 
cytoplasmic with a stippled pattern, although some nuclear staining was also noted (Figure 1A). For 126 
AGR2 38 (27.5%) BMs were negatively stained, whilst 100 (72.5%) showed cytoplasmic staining. 127 
BMs from the posterior fossa that included cerebellar cortex showed incidental positive staining of 128 
what appeared to be the granule cells, but this did not affect the tumour staining analysis (Figure 1B).  129 
Assessment for S100P staining was positive (nuclear and cytoplasmic) in 102 BM (73.9%) cases, 130 
negative in 36 (26.1%). In areas of white matter adjacent to tumour, occasional astrocytes were seen 131 
to stain with anti-S100P antibody (Figure 1C), however, morphology and staining of serial sections 132 
with GFAP clarified that these were not tumour cells, thus avoiding any false positives. Glial staining 133 
for the purposes of this study was not considered further. For S100A4, 32 BMs (23.2%) were negative 134 
and 106 (76.8%) stained to some degree (Figure 1D). Staining was both nuclear and cytoplasmic, 135 
however smooth muscle and endothelium were also seen to stain avidly with this antibody as noted 136 
previously. There was no staining of astrocytes nor peritumoral staining for S100A4 or OPN (Figure 137 
1A,D).  The heterogeneity of tissue staining was better appreciated in lower power micrographs 138 
(Supplementary Data, Figure S1). There was no staining with antigen-blocked immune serum (Figure 139 
1) or with non-immune serum (Supplementary Data, Figure S2) as negative controls. Melanoma cases 140 
required a different coloured chromogen (Supplementary Data, Figure S3). The majority of BMs (113 141 
or 81.9%) showed no immunoreactivity for FANCD2: only 25 (18.1%) showed weak cytoplasmic 142 
staining and there was no nuclear staining in any cases.  143 
 144 
Association between MIPs and primary cancer type, clinical features 145 
Figure 2 and Supplementary Data (Table S2) show positive BM staining for each MIP by primary 146 
cancer type. There was no significant variation in BM staining for the S100 proteins by primary 147 
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cancer (Fisher’s Exact test for S100P p=0.279, S100A4 p=0.135). There were significantly more 148 
AGR2 positive colorectal and non-small cell lung cancer BMs than expected (p<0.001) but fewer 149 
OPN positive lung cancer BMs of all types (p=0.033).  Importantly, none of the clinical features 150 
which are traditionally used to determine prognosis in patients with BMs (Gaspar et al, 1997b; 151 
Sperduto et al, 2008) were associated with positive staining for any of the MIPs (summarised in 152 
Supplementary Data, Table S3).  153 
 154 
Association of MIPs with patient outcomes 155 
Median OS was 7.67 months (95% CI: 4.45 – 10.89) and only age < 60 years (HR= 0.56, 95% CI: 156 
0.33 - 0.94, p=0.028) was found to be independently associated with prolonged OS. There was no 157 
relation between positive MIP staining and OS (Figure 3A & Supplementary Data, Table S4). 158 
Amongst patients receiving adjuvant WBRT, OS was 3.43 months (95% CI: 1.36 – 5.51) for OPN 159 
negative cases but 11.20 months (95% CI: 7.68 – 14.72) for positive cases, Log Rank test, p<0.001. 160 
There was no confounding difference in age (Student’s t-test, p=0.118), performance status (p=0.331) 161 
nor other clinical factors such as radioresistant tumour types (e.g. renal cancer BMs) between the 162 
groups to explain this effect. Different cut-offs for positive staining were used to check if the 163 
percentage of tumour cells staining positive related to response to WBRT.  There was a non-164 
significant trend to prolonged median OS after WBRT with increasing percentage of positively OPN 165 
stained tumour cells: 11.2 months if > 5%, 13.9 months if >25% and 15.9 months if >50% positively 166 
stained.  167 
Thirty solitary metastases that were completely resected showed intracranial progression at a median 168 
of 18.9 months from surgery (95% CI: 6.54 – 31.26). Table 2 lists the clinical factors associated 169 
significantly with prolonged PFS alongside MIP staining. As illustrated in Figure 3B, negative 170 
staining for S100A4 in the resected BM was the only factor independently associated with a longer 171 
PFS (HR for intracranial progression = 0.17, 95% CI: 0.04 – 0.74, p=0.018). Tumour heterogeneity 172 
was assessed using different cut-offs for positive staining (see Supplementary Data, Figure S1 for 173 
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examples) and there was no difference in clinical factors or outcomes when assessing tumours with 174 
>5%,>25%,or >50% of S100A4 positive staining cells, illustrated for PFS in Figure 3C.  175 
 176 
Subtypes of BMs from common primaries 177 
Forty patients with breast cancer were assessed separately and staining by subtype of breast 178 
carcinoma is shown in Supplementary Data, Table S5. The median OS was 14.23 months (95% CI 179 
9.21 – 19.26) and negative staining for S100A4 was independently associated with longer OS (HR for 180 
death = 0.26, 95% CI: 0.08 - 0.80, p=0.019, Figure 4A) along with age <60 years (HR = 0.3, 95% CI: 181 
0.11 - 0.81, p=0.017) and post-operative chemotherapy (HR = 0.12, 95% CI: 0.02 – 0.61, p=0.010). 182 
As an additional check, when the disease specific- graded prognostic assessment (DS-GPA) factors 183 
(Sperduto et al, 2010) for breast BM (age, subtype of carcinoma and performance status) were 184 
combined in a model, the predictive value of staining for the protein persisted (HR for death in 185 
S100A4 negative cases = 0.58, 95% CI: 0.35 - 0.96, p= 0.033).  Intracranial progression occurred in 186 
15/ 40 breast carcinoma patients and the 11 / 15 S100A4 positive cases showed significantly earlier 187 
intracranial progression (median 9.77 months, 95% CI: 8.28 – 11.25) than the 4 /15 negatively stained 188 
cases (median 27.03 months, 95% CI: 18.46 – 35.60, Log Rank test, p=0.023) (Figure 4B).    189 
Non-small cell lung cancer patients had a median OS of 6.43 months (95% CI: 3.45 – 9.43) and 27 190 
out of 38 received WBRT, this being the only factor associated with increased OS (HR of death if 191 
WBRT omitted = 3.07, 95% CI: 1.08 – 8.69, p=0.035) regardless of incorporating MIP staining or the 192 
DS-GPA factors. Only five of 38 patients developed intracranial progression - reflecting the burden of 193 
systemic disease on survival in these cases – but notably all of those BMs stained positively for 194 
S100A4. 195 
There were 16 malignant melanoma cases and their median OS was 5.53 months (95% CI: 0.1 – 196 
16.9). Incorporating the DS-GPA factors (number of BMs and performance status) with MIP staining 197 
showed that positive staining for S100A4 in the BM (13/16 cases) was the only factor independently 198 
associated with decreased OS (HR for death in negatively stained cases = 0.09, 95% CI:0.01 - 0.97, 199 
9 
 
p=0.047). Only 5/ 16 patients developed intracranial progression, and notably all of the S100A4 200 
positive BMs progressed.  201 
 202 
Validation and investigation of intra-tumoral heterogeneity 203 
Unselected BM samples from 24 prospectively treated patients were analysed, taking 1% as the cut-204 
off for positive staining; 88% were S100A4 positive and 83% were OPN positive. This prospective 205 
validation cohort showed no significant differences from the retrospective cases in patient age, 206 
gender, size of operated metastasis, control of systemic disease, extracranial metastases or use of 207 
adjuvant chemo- and radiotherapy (Supplementary Data, Table S1). 19 / 24 patients received adjuvant 208 
WBRT and, as in the retrospective series, this conferred a survival advantage in OPN positive (6.3 209 
months if irradiated vs 2.7 months if not, Log Rank test, p=0.001) but not in OPN negative cases 210 
(p=0.08).  In total 9 of 24 cases showed intracranial progression and all of these were S100A4 positive 211 
(Supplementary Data, Figure S4). In the course of resection additional samples were obtained using 212 
image guidance at the leading edge of the BMs and all the MIPs showed a non-significant trend to a 213 
higher percentage of cells positive at the leading edge (Wilcoxon matched pairs analysis, p>0.05 for 214 
each MIP). S100A4 showed the greatest difference between percentage of positively staining cells at 215 
the edge and in the interior (ratio of 4.3 vs. 1.7 for OPN, 2.5 for AGR2, 3.2 for S100P) although this 216 
ratio was not associated with any clinical outcome, nor was it related to primary tumour type.  217 
 218 
Relationship of S100A4 staining to development of brain metastases 219 
Given the relation of S100A4 overexpression to progression, the association of S100A4 with risk of 220 
BMs in patients with known cancer was investigated. In a series of breast cancer patients with BMs, 221 
22 / 27 of primary tumours (81%) were S100A4 positive compared to 18/117 (15%) in a group with 222 
known non-metastatic breast cancer (Rudland et al, 2000) as shown in Figure 5 (Fisher’s Exact test, 223 
p<0.0001). The median time until development of BMs after diagnosis of breast cancer was 25.5 224 
10 
 
months (95% CI: 20.1 – 30.9) and was no shorter in the S100A4 positive cases (Log Rank test 225 
p=0.67). 226 
 227 
Discussion 228 
 229 
We have shown for the first time that proteins which are (i) mechanistically proven to be involved in 230 
extracellular matrix adhesion and cell migration in vitro, (ii) convey a metastatic phenotype - 231 
including to brain - when overexpressed in animal models and (iii) are predictive of clinical outcomes 232 
in a variety of solid organ cancer cohorts, are also highly expressed at the protein level in human BMs 233 
and associate with important clinical outcomes. Previous publications have shown that the degree of 234 
immunohistochemical staining of carcinoma cells for the proteins described, OPN (Rudland et al, 235 
2002), S100A4 (Rudland et al, 2000), S100P (Wang et al, 2006), AGR2(Barraclough et al, 2009) and 236 
FANCD2 (Rudland et al, 2010) reflect the level of each particular protein in the specimens.  237 
 238 
Association of S100A4 with patient outcomes and possible clinical applications  239 
We found comparable outcomes to other large, multicentre series of BM patients with age and 240 
performance status again shown to be strong predictors of OS (Gaspar et al, 1997a; Sperduto et al, 241 
2008).  Additionally, we find that S100A4 was expressed in all progressing melanoma and non-small 242 
cell lung cancer BMs as well as being independently associated with time to intracranial progression 243 
in breast cancer - where patients had the longest overall survival time - but not in lung cancer, where 244 
patients were less likely to die from their brain disease. This result holds true even when known 245 
clinical predictors for each cancer type are incorporated into multivariate models (Sperduto et al, 246 
2008) and suggests that S100A4 has some role in spreading in the brain microenvironment; in support 247 
of this suggestion the protein was seen to be expressed at the leading edge of BMs in image-guided 248 
samples. It is known that S100A4 can reduce the formation of focal adhesions between cellular 249 
filopodia and the extracellular matrix via myosin heavy chain IIA to cause cell migration, invasion 250 
11 
 
and metastasis (Gross et al, 2014) and thus it may represent a novel biological marker  or a potential 251 
drug target. There is already interest in this protein as a monocloncal antibody target in metastatic 252 
melanoma and pancreatic cancer, following evidence that this family of proteins is a marker of 253 
aggressive, advanced tumours (Weide et al, 2013) (Hernandez et al, 2013).  254 
 255 
Relationship of different proteins to BM development 256 
Although staining for three MIPs is somewhat elevated in these BMs, only that for S100A4 shows a 257 
significant association with clinical outcomes in the form of time to intracranial progression in all 258 
BMs (Figure 3), and OS in breast cancer (Figure 4) and melanoma BMs. Since positive staining for 259 
S100A4 occurs more often in advanced rather than in early breast cancers in contrast to the other three 260 
MIPs (de Silva Rudland et al, 2011; Winstanley et al, 2013), it may be that only S100A4 plays a role 261 
in the subsequent progression of those patients with BMs, whilst the other three MIPs stimulate earlier 262 
and different steps in the metastatic pathways. In support of this we show for the first time that 263 
S100A4 is overexpressed in brain metastatic over non-metastatic breast cancers. Conversely, recent 264 
analysis of protein expression in the MDA-MB-231BR breast cancer cell line metastatic to mouse 265 
brains showed that S100A4 was under expressed compared to the parent MDA-MB-231 line (Dun et 266 
al, 2015). However this report did not distinguish intra-from extracellular expression and was 267 
conducted on a triple negative cell line whereas we found mostly HER2 and luminal subtypes in our 268 
patient group of BM. Moreover, since most of the proteome changes in 231 BR cells were decreases 269 
in individual protein levels, it is not clear whether the reduction in these proteins is important in 270 
metastasis or the proteins are down-regulated because they have been selected against during the 271 
multiple cycles of injection and recovery from the immunosuppressed mice (Dun et al, 2015). The 272 
latter argument is more consistent with our earlier findings in thymectomised syngeneic rats and 273 
genetically immune-suppressed mice (Rudland et al, 1989).  274 
 275 
OPN as a marker of radiosensitivity 276 
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Although WBRT remains a pragmatic and readily available adjuvant treatment for BMs, there is 277 
concern regarding the cognitive effects in survivors and alternative post-operative management 278 
strategies are proposed. Using a simple BM marker to stratify patients as good or poor radiation 279 
responders would therefore be an extremely useful clinical tool. Regarding therapeutics, cilengitide, 280 
an αvβ3/αvβ5 integrin inhibitor known to have efficacy in the brain microenvironment, appears to 281 
enhance radiation response in preclinical breast cancer BM models (Lautenschlaeger et al, 2013). It is 282 
therefore plausible that overexpression of OPN, an αvβ3/αvβ5 integrin ligand, in the BM may predict 283 
prolonged OS from adjuvant WBRT and this result merits further investigation. 284 
 285 
Limitations  286 
Although retrospective data - particularly for performance status - is undesirable, a range of common 287 
cancers are represented in sufficient numbers to allow lung, breast and melanoma to be explored 288 
separately and there were no missing data fields. To validate either protein as a clinical biomarker, a 289 
larger prospective study would be required recording tumour and possible also serum IHC levels of 290 
S100A4 and OPN alongside clinical outcomes (Dancey et al, 2010). MRI of asymptomatic patients at 291 
regular, e.g. 2 monthly follow up, would have captured more detail on intracranial progression, 292 
reducing censored data in this category and clarifying if this were at the site of surgery, distant or 293 
leptomeningeal (an under-recognised phenomenon).  294 
 295 
Conclusions  296 
Proteins known to be involved in cellular adhesion and migration in vitro and metastasis in vivo are 297 
significantly expressed in human brain metastases and may be useful biomarkers of intracranial 298 
progression and radiosensitivity. 299 
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Figure legends 436 
 437 
Figure 1: Staining for the Metastasis-Inducing Proteins in human brain metastases. A. Osteopontin in 438 
the tumour cytoplasm of a lung adenocarcinoma metastasis with some staining of the neuropial 439 
material in adjacent white matter. White matter and microglia, astrocytes were easily distinguished 440 
morphologically from tumour cells and their staining was not counted when scoring slides. B. AGR2 441 
staining was seen mainly in the cytoplasm with no uptake in surrounding white matter as shown in 442 
this lung adenocarcinoma metastasis. C. S100P staining in a lung adenocarcinoma with adjacent white 443 
matter shown – this protein, as in previous studies, was overexpressed in connective tissue and 444 
smooth muscle. D. Nuclear and cytoplasmic staining for the protein S100A4 is shown in a brain 445 
metastasis from a breast carcinoma with avid staining of the endothelium also demonstrated.  Taken at 446 
x100 and x400 magnification with scale bars shown (=100µm) and antigen-blocked immune serum 447 
controls given alongside. 448 
 449 
Figure 2: Binary heat map showing the immunohistochemical staining of 138 brain metastases 450 
removed at neurosurgery for the Metastases-Inducing Proteins osteopontin (OPN), S100A4, S100P, 451 
anterior gradient 2 (AGR2) and FANCD2. Brain metastases are grouped by the primary cancer of 452 
origin with red squares showing positive staining of any degree (>1% carcinoma cells stained) and 453 
green squares indicating negative staining. 454 
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 455 
Figure 3: (A) Survival of patients with and (B,C) disease progression of 138 brain metastases from 456 
different primary sites. A. Proportion of patients surviving is plotted against overall survival time as  457 
Kaplan-Meier curves for positive (>1% carcinoma cells stained) and negative (<1% carcinoma cells 458 
stained) immunohistochemically stained brain metastases for S100A4. Survival time was not 459 
significantly associated with staining for S100A4 (Log rank test, p=0.222). B. Proportion of patients 460 
surviving without intracranial progression is plotted against time as Kaplan-Meier curves for positive 461 
and negative immunohistochemically stained brain metastasis for S100A4. These patients had a 462 
grossly resected tumour. Median time to progression was significantly shorter in cases staining 463 
positive for S100A4 (11.77 months, 95% CI: 7.07 – 16.47) versus negatively stained cases (27.03 464 
months, 95% CI: 16.49 – 37.57), Log Rank test, p=0.007. This effect persisted in multivariate Cox 465 
analysis (HR 0.166, 95% CI: 0.04 – 0.74, p=0.018). C. S100A4 positive cases in B above are 466 
subdivided into categories by the proportion of carcinoma cells in the specimen staining to various 467 
degrees for the S100A4 protein (pooled Log-Rank test (4 df) = 9.806, p = 0.044). Ticks indicate 468 
censored data in all panels. 469 
 470 
Figure 4: (A) Survival of patients with and (B) disease progression of 40 brain metastases from 471 
primary breast cancer stained for S100A4. A. Proportion of patients surviving is plotted against 472 
overall survival time as Kaplan-Meier curves for positive (>1% carcinoma cells stained) and negative 473 
(<1% carcinoma cells stained) immunohistochemically stained brain metastases for S100A4. Positive 474 
staining in the brain metastasis was significantly associated with shorter overall survival in 475 
multivariate (Cox) analysis (HR of 0.26, 95% CI: 0.08 to 0.80, p=0.019) adjusted for age using the 476 
average covariate method (Makuch, 1982). B. Proportion of patients surviving without intracranial 477 
progression is plotted against time to intracranial progression as Kaplan-Meier curves for positive and 478 
negative immunohistochemically stained brain metastases for S100A4. Fifteen out of the 40 479 
developed intracranial progression and of these, 11/15 cases which were positively stained for 480 
S100A4 showed significantly earlier progression (median 9.77 months, 95% CI: 8.28 – 11.25) than 481 
the 4 negatively stained cases (median 27.03 months, 95% CI: 18.46 – 35.60, Log Rank test, 482 
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p=0.023). Ticks indicate censored data in all panels. 483 
 484 
 485 
Figure 5: Comparison of staining for S100A4 in non-metastatic and brain metastatic breast cancers. 486 
The proportion of primary tumours staining positively for S100A4 in a group of previously reported 487 
patients (de Silva Rudland et al, 2011) with non-metastatic breast carcinoma surviving over 20 years 488 
was found to be significantly different from that of a group of breast carcinoma cases known to be 489 
brain metastatic (Fisher’s Exact test, p<0.0001). There was no significant increase in S100A4 490 
positivity in the breast BMs themselves compared to the primary breast tumours nor in the proportion 491 
of S100A4 positive staining in BMs from other primaries compared to those from primary breast 492 
cancer (Fisher’s Exact test, p=0.39, p=0.27 respectively). 493 
 494 
 495 
 496 
Abbreviations used 497 
AGR2 = anterior gradient 2; APES = 3 aminopropyltriethoxy; BM = brain metastasis; BSA = bovine 498 
serum albumin; CI = confidence interval; DS-GPA = disease specific graded prognostic assessment; 499 
ECM = extracellular matrix; FANC = Fanconi anaemia complementation group; HR = hazards ratio; 500 
IHC = immunohistochemistry; MIPS = metastasis-inducing protein; MRI = magnetic resonance 501 
imaging; OPN = osteopontin; OS = overall survival; PFS = progression free survival; RANO = 502 
response assessment in neuro-oncology; WBRT = whole brain radiotherapy 503 
 504 
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*30Gy/5# most common 
Age at surgery (median, range) 59.9 years ( 20.3 – 82.4) 
 Number Percentage total 
Karnofsky performance status 
< 70% 101 73.2% 
> 70% 37 26.8% 
Location of operated metastasis 
Posterior fossa 33 23.9% 
Supratentorial 105 76.1% 
Number of brain metastases 
Multiple 26 18.8% 
Solitary 112 81.2% 
Size of operated metastasis 
(diameter) 
< 30mm 56 40.6% 
> 30mm 82 59.4% 
Primary cancer controlled? 
No 29 29.9% 
Yes 68 70.1% 
Extra-cranial metastases? 
Absent 91 65.9% 
Present 47 34.1% 
Synchronous presentation: 
primary and brain metastases? 
No 97 70.3% 
Yes 41 29.7% 
Primary cancer histology 
Bladder 3 2.2% 
Breast 40 29% 
Endometrial 2 1.4% 
Colorectal 12 8.7% 
Renal 7 5.1% 
Melanoma 16 11.6% 
Non-small cell lung 38 27.5% 
Oesophagus 5 3.6% 
Ovarian 2 1.4% 
Pancreas 1 0.7% 
Prostate 2 1.4% 
Small cell lung 8 5.8% 
Squamous cell 2 1.4% 
Type of operation 
Biopsy 1 0.7% 
Gross total 
resection 127 92% 
Subtotal resection 10 7.2% 
Whole brain radiotherapy after 
neurosurgery* 
No 33 23.9% 
Yes 105 76.1% 
Chemotherapy after neurosurgery 
No 86 62.3% 
Yes 52 37.7% 
Table 2. Clinical and biological factors associated with prolonged progression free survival time (PFS) 
from resection to first brain progression of a metastasis. Significant relations highlighted (*). 
Factor  
(events / total) 
Median PFS / months  
(95% CI) 
Log rank comparison 
& significance 
HR (95% CI) & significance in 
Cox regression 
Age 
<60 years (26 / 63) 
>60 years (4 / 62) 
11.3 (3.49 – 19.1) 
Not reached 
 
4.813, p= 0.028* 
0.97 (0.94 – 1.01), p=0.059 
Performance status 
KPS>70% (30 / 90) 
KPS<70% (0 / 35) 
18.9 (6.54 – 31.26) 
Not reached 
 
3.245, p=0.072 
 
S100A4 staining 
Positive (26 / 97) 
Negative (4 / 28) 
S100P staining 
Positive (24 / 95) 
Negative (6 / 30) 
AGR2 staining  
Positive (20 / 95) 
Negative (10 / 30) 
OPN staining  
Positive (28 / 110) 
Negative (2 / 15) 
FANCD2 cytoplasmic 
staining  
Positive (4 / 23) 
Negative (26 / 102) 
 
11.77 (7.07 – 16.47) 
27.03 (16.49 – 37.57) 
 
15.2 (6.16 – 24.25) 
24.57 (0 – 49.5) 
 
21.77 (10.85 – 32.69) 
11.10 (8.06 – 14.14) 
 
19.9 (6.25 – 31.5) 
15.2 (NA) 
 
 
21.77 (6.88 – 36.66) 
15.20 (4.96 – 25.44) 
 
7.295, p=0.007* 
 
 
0.623, p=0.43 
 
 
1.117, p=0.291 
 
 
0.035, p=0.851 
 
 
 
0.113, p=0.737 
 
 
0.17 (0.04 – 0.74), p=0.018* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
